About Taivex
About Taivex
Development of Targeting Agents
Improve of health
Improve of the quality of life for cancer patients
Benefit of people and the community
Company Profile
公司簡介
Taivex Therapeutics Corporation was established in Taipei in 2010 and cofounded by Taivex LLC (CA, USA) and china petrochemical development corporation (CPDC). Taivex focus on developing oncology drugs to overcome the unmet medical needs and increased drug price. Taivex take the responsibility and a commitment to sustainable development respecting the needs of the individual, the society and the environment.
Milestone
沿革里程碑
2022
T-1101 be invited for an oral presentation at IDDST-2023
2021
- T-1201 get US and TW IND approval for Phase I study
- T-1201initiate Phase I study in Taiwan
- T-1301 get US and TW IND approval for Phase I study in Taiwan
- T-1301 initiate Phase I study in Taiwan
- T-1501 Technique transfer from National Health Research Institutes (NHRI)
2019
- T-1301 Technique transfer from National Health Research Institutes (NHRI)
2018
T-1201 granted the 14th Tien Te Lee Biomedical Young Scientists Award
2017
- T-1101 get TW IND approval for Phase I study
- T-1101 initiate Phase I study in Taiwan
- T-1201 granted 2017 Taipei Biotech Award-Technology Transfer Gold Medal Award
2016
- T-1101 get US IND approval for Phase I study
- T-1201 Technique transfer from National Health Research Institutes (NHRI)
2015
T-1201 co-development with National Health Research Institutes (NHRI)
2011
T-1101 granted the MOEA 2011 Breakthrough Innovation of the Year Award
2010
- Company established
- T-1201 co-development with Development center for Biotechnology (DCB)
Business Model
營運模式
Organization
組織架構
